TPCW
RVMD icon

TD Private Client Wealth’s Revolution Medicines RVMD Stock Holding History

TD Private Client Wealth’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.4K Buy
125
+35
+39% +$5.11K ﹤0.01% 1016
2026
Q1 		$8.75K Buy
90
+8
+10% +$808 ﹤0.01% 1120
2025
Q4 		$6.53K Buy
82
+2
+3% +$131 ﹤0.01% 1128
2025
Q3 		$3.74K Hold
80
– – ﹤0.01% 1175
2025
Q2 		$2.94K Buy
+80
New +$3.07K ﹤0.01% 1177

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

TD Private Client Wealth's RVMD Position: Q2 2026 in Review

TD Private Client Wealth increased its Revolution Medicines (RVMD) stake by 39% in Q2 2026, buying an estimated $5.11K and bringing the position to 125 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1016.

TD Private Client Wealth first reported a position in RVMD in Q2 2025 and has held it in 5 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • TD Private Client Wealth held 125 shares of Revolution Medicines worth $23.4K as of Q2 2026.
  • TD Private Client Wealth bought 35 Revolution Medicines shares in Q2 2026, an estimated $5.11K.
  • Revolution Medicines made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1016 holding.
  • TD Private Client Wealth first reported a position in Revolution Medicines in Q2 2025 and has held it in 5 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.